Personalized vaccines for a type of brain cancer mounted an immune system response against the tumors in a small number of patients, according to data from two new studies, an early indication that immunotherapy might hold some promise for targeting the difficult-to-treat cancers.
The studies, published Wednesday in the journal Nature, underscore how wily glioblastoma, or GBM, is in evading attacks by the immune system on tumors: The patients did not see the course of their disease change, and even patients who generated an immune response died from their cancers.
Still, experts said, the early-stage clinical trials suggest researchers may be able to find ways to improve immunotherapies and the ways in which they are delivered to develop effective cancer vaccines.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect